This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Jim Cramer

Real Money Columnist


Jim Cramer is one of America's most recognized and respected investment pros and media personalities. He runs Action Alerts PLUS, a charitable trust portfolio. In 1996, Jim founded TheStreet, one of the "most visited" financial media websites for individual to institutional investors. Jim also writes daily market commentary for TheStreet's Real Money premium service, and participates in video segments on TheStreet TV. He also serves as host of CNBC's "Mad Money" television program.


Jim graduated magna cum laude from Harvard College, where he was president of The Harvard Crimson. He went on to earn a law degree from Harvard Law School in 1984. From there Jim joined Goldman Sachs, where he worked in sales and trading. In 1987, he left Goldman to start his own hedge fund. While still managing his fund, Jim helped start Smart Money for Dow Jones. He is the author of Confessions of a Street Addict, You Got Screwed, Jim Cramer's Real Money, Jim Cramer's Mad Money, Jim Cramer's Stay Mad for Life and, his newest book, Jim Cramer's Getting Back to Even. Jim has written for Time magazine and New York magazine and has been featured on CBS' 60 Minutes, NBC's Nightly News with Brian Williams, Meet the Press, Today, The Tonight Show, Late Night and MSNBC's Morning Joe.

By This Author:
Page 3 of 453
Video

Jim Cramer and Stephanie Link Preview 1Q Bank Earnings

By Jim Cramer

The biggest banks in the U.S. will begin to release 2014 first-quarter results next week and investors like Jim Cramer and Stephanie Link will watch to see where banks are making money.

02:51PM 04/02/14

Video

Cramer & Dicker: Oil Prices Drop Under $100 on Weak China Data

By Jim Cramer

Despite oil prices retreating due to data showing slowing Chinese manufacturing and easing Ukraine tensions, Dan Dicker still sees opportunity in U.S. oil companies.

01:45PM 04/02/14

Video

Jim Cramer is Neutral on Mannkind's Afrezza Inhaled Insulin

By Jim Cramer

TheStreet's Jim Cramer says he is completely neutral on Mannkind and sometimes it's better to admit you don't know where something is going.

01:00PM 04/02/14

Video

Jim Cramer Is Looking for In-line March Jobs Number

By Jim Cramer

Jim Cramer says the latest ADP jobs number shows a 'mixed picture' in the U.S. labor market and that even though autos have been strong, which is a big driver, mortgages are down and housing may not be a big number.

11:31AM 04/02/14

Video

Jim Cramer Says You Can't Ignore Stocks in the Oil Space

By Jim Cramer

TheStreet's Jim Cramer says one of the themes investors should pay close attention to is oil and the opportunities for investment it presents.

07:00PM 04/01/14

Video

Jim Cramer Says Watch Celgene, Salesforce.com for Growth in Q2

By Jim Cramer

TheStreet's Jim Cramer says investors need to see money come back to high-growth names, which have seen a shrinking price-to-earnings multiple.

03:08PM 04/01/14

Video

Jim Cramer Says Watch Proctor & Gamble, Coach, Nike on China Data

By Jim Cramer

Jim Cramer says markets appear to be brushing-off weak PMI data from China because expectations were already low, and while industrials may be slowing down, consumption names are gaining speed.

11:15AM 04/01/14

Video

Cramer: JNJ Deal Will Lead to a Buyback and Much More Upside

By Jim Cramer

Johnson & Johnson is selling its Ortho-Clinical Diagnostics business to The Carlyle Group for $4 billion.

09:14AM 04/01/14

Video

Jim Cramer on Dish Merger, Solar Investing and Starbucks

By Jim Cramer

Jim Cramer answers viewer questions on Dish Networks, solar investing and Starbucks.

10:48AM 03/31/14

Video

Jim Cramer Says Keep an Eye on 'New Pharma' as an Investment Theme

By Jim Cramer

TheStreet's Jim Cramer says newer pharmaceutical companies, like Celgene (CELG), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN), should be bought on any weakness because they have the potential to perform extremely well and may be better buys than Pfizer, Merck, Bristol-Myers and Eli Lilly.

08:00AM 03/29/14

Page 3 of 453

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs